Treating and Preventing HIV With Generic Drugs

Generic antiretroviral agents have had a dramatic effect on outcomes in developing nations, and their availability in developed countries is rapidly expanding as more brand-name ...

Improving Adherence to ART in HIV

The rapidly developing landscape of antiretroviral therapy adherence monitoring has great potential for clinical application, but cost-effectiveness and feasibility studies are needed to define the ...

Preventing HIV, STIs Through School-Based Programs

Although a positive impact on behavior change has been reported following the implementation of curriculum-based programs, there is a lack of clear evidence that school-based ...

HPV Infection in HIV Increases Cervical Cancer Risk

Women with HIV have an increased risk for persistent HPV infection, which frequently progresses to cervical cancer, and they should be warned of their increased ...

Pausing ART: Safety and Ethical Considerations

Dr Gianella Weibel talks with Dr Li and Dr Dubé, investigators of a new study from the AIDS Clinical Trials Group, which uses an intensively ...

Microbiome and HIV

The interactions between HIV, ART, human sexual behavior, and the gut microbiome are complex and sorting out these interactions will be important to design future ...

Increasing HIV Viral Suppression Rates Through Financial Incentives

Use of incentives makes the most sense with disadvantaged populations including homeless, drug users, and people in developing countries.
HIV/AIDS

Latest News

Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection

Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection

Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.

Novel Digital ELISA May Detect, Quantify Low HIV p24 Concentrations in CSF

Novel Digital ELISA May Detect, Quantify Low HIV p24 Concentrations in CSF

More comprehensive research will be needed to further investigate cerebrospinal fluid p24 by high-sensitivity assay as a marker for neurocognitive impairment during poorly controlled HIV and as a marker for HIV central nervous system reactivation during latency reversal therapy.

Age, Exposure to Antiretrovirals Affect Diabetes Risk in HIV

Age, Exposure to Antiretrovirals Affect Diabetes Risk in HIV

Interventions for diabetes prevention and management may be needed to reduce the risk for diabetes in patients with HIV.

About Half of Pregnant Women With HIV Have C-Sections

About Half of Pregnant Women With HIV Have C-Sections

About half of pregnant women with HIV infection underwent cesarean delivery between 1998 and 2013.

HIV-1 Susceptibility Increases in Late Pregnancy and Postpartum Periods

HIV-1 Susceptibility Increases in Late Pregnancy and Postpartum Periods

Researchers assessed the differential risk of acquiring HIV-1 infection across reproductive stages by calculating per-coital-act risk for each stage and comparing with nonpregnant times.

Single-Tablet HIV Regimen Improves Retention in Care and Virologic Suppression

Single-Tablet HIV Regimen Improves Retention in Care and Virologic Suppression

Investigators assessed adherence to antiretroviral therapy, retention in care, and virologic outcomes in patients receiving once-daily single-tablet and multiple-tablet antiretroviral therapy regimens.

Effects of Peer Navigation Intervention on HIV Viral Suppression After Release From Jail

Effects of Peer Navigation Intervention on HIV Viral Suppression After Release From Jail

The effects of a peer navigation intervention on HIV viral suppression in previously incarcerated individuals were examined.

Tenofovir Alafenamide Plus Emtricitabine Safely and Effectively Treats HIV-1

Tenofovir Alafenamide Plus Emtricitabine Safely and Effectively Treats HIV-1

A head-to-head comparison was made between HIV-1 treatment regimens containing tenofovir alafenamide plus emtricitabine with those containing abacavir plus lamivudine.

Text Messaging Interventions Do Not Improve HIV Outcomes

Text Messaging Interventions Do Not Improve HIV Outcomes

Text messaging may be a promising strategy for support and engagement in HIV care.

Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV

Worse Cognitive Outcomes Associated With CMV Antibodies Following ART for HIV

Investigators sought to determine the association between antiretroviral therapy and cytomegalovirus infection in individuals with HIV, as well as the potential impact of both on neurocognitive performance.

Feature Article

Vagus Nerve Stimulation May Improve HIV-Associated Depression

Vagus Nerve Stimulation May Improve HIV-Associated Depression

Transcutaneous vagus nerve stimulation could provide a safe alternative treatment in HIV-depression by targeting both depression and other comorbidities that can burden people living with HIV.

Adolescents at Risk for HIV Should Be Offered PrEP

Adolescents at Risk for HIV Should Be Offered PrEP

Experts discuss new findings supporting the need for PrEP in adolescents and discuss the continued debate surrounding parental consent and other relevant issues.

Assessing the Risk Factors of Neurocognitive Decline in HIV+ Individuals

Assessing the Risk Factors of Neurocognitive Decline in HIV+ Individuals

The incidence of neurocognitive impairment is high in HIV-infected population, despite the introduction of combination antiretroviral therapy (CART).

Why Patients Discontinue ART— and What You Can Do to Stop It

Why Patients Discontinue ART— and What You Can Do to Stop It

Learn more about when stopping antiretroviral therapy (ART) may be necessary, why patients discontinue ART, predicting viral suppression, and predicting and encouraging adherence.

Bone Loss and Fracture Risk in Patients With HIV: What We Know So Far

Bone Loss and Fracture Risk in Patients With HIV: What We Know So Far

In addition to prevention measures, switching off the ARTs associated with bone loss and administering intravenous bisphosphonate, a bone resorption inhibitor, can be an effective strategy for preventing bone loss seen in HIV-infected individuals.

Aging With HIV: Expert Insights on Complications and Challenges

Aging With HIV: Expert Insights on Complications and Challenges

Three HIV experts provide their insights into aging-related challenges and complications faced by people living with HIV.

ART and PrEP: How Technological Advances Can Improve Adherence

ART and PrEP: How Technological Advances Can Improve Adherence

Several technological advances have been developed to improve adherence to antiretroviral and preexposure prophylaxis therapy.

Last Gift Study: A Participant's Perspective on End-of-Life HIV Research

Last Gift Study: A Participant's Perspective on End-of-Life HIV Research

Dr Sara Gianella Weibel talks with Anthony B, a patient with HIV and end-stage amyotrophic lateral sclerosis and the first participant enrolled in the "Last Gift" end-of-life study, about his experience as part of this new end-of-life model to study HIV persistence.

Last Gift Study: Community Perspective on End-of-Life HIV Research

Last Gift Study: Community Perspective on End-of-Life HIV Research

Dr Sara Gianella Weibel talks with Jeff Taylor, community activist and long-term HIV survivor, about a new end-of-life model to study HIV persistence.

Last Gift Study: End-of-Life HIV Research

Last Gift Study: End-of-Life HIV Research

Dr Sara Gianella Weibel talks with Dr Davey Smith, head of the Division of Infectious Disease at the University of California, San Diego, about a proposed new model to study HIV persistence, called the Last Gift study.

Slideshows

SIGN UP FOR FREE E-NEWSLETTERS